Torough David, Abuja

Stakeholders across health sectors have called for urgent, coordinated investment in prevention, equitable HPV vaccine access and harmonized health data to accelerate progress towards elimination of cervical cancer across Africa.

They made the call on Wednesday, during a panel session with the Theme ”Accelerating Cervical Cancer Elimination in Nigeria, From Policy to Practice”.

Head of Division, Maternal, Newborn, Child and Adolescent Health, Africa CDC, Dr Fidele Ngabo Gaga, highlighted its efforts to harmonise and aggregate health data across all 55 African Union (AU) Member States.

“We are developing a continent-wide data-sharing agreement and centralised repository to support data upstreaming and policy development.

“The goal is to present unified data at AU Summits, helping countries make evidence-based decisions,” Gaga said:

Prof. Imran Morhason-Bello, a leading gynaecologic oncologist from the University College Hospital, Ibadan, made a compelling financial case for prioritising prevention over treatment.

“Screening just between 2023 and 2027 will cost Nigeria N351 billion.

“But treating 10,000 women with invasive cervical cancer from 2027 to 2030 could cost us N1.4 trillion. Prevention is not only more humane, it is far more cost-effective,” he said.

Morhason-Bello also addressed innovations such as self-sampling for HPV testing, already being implemented in Nigeria through implementation science.

“Women receive a self-sampling kit, return it the same day, and positive results are treated before noon.

“It is happening in markets and schools. It is not a pilot, it is real.

“We have even developed a mobile app (available in multiple languages and offline) to guide women through the self-sampling process, increasing accessibility in low-resource settings,” he said.

External Affairs Director for MSD, Sub-Saharan Africa, Vuyo Mjekula, addressed one of the most common myths around the HPV vaccine rollout.

“Let me be clear, there is no shortage of HPV vaccines. If anyone tells you otherwise, call me directly. The real issue is equity and strategic allocation,” she said.

Mjekula recalled early proposals that included boys in HPV vaccination efforts, but warned that without careful planning, some countries would be left out entirely.

She called for one national policy that ensures equitable access to vaccines and services, especially for the most vulnerable girls.

“This is not about science alone. A dose costing N125,000 may be affordable to some, but to a woman in a rural village, it is like N10 million.

“If she must choose between survival and feeding her children, the answer is obvious,” she said.

She applauded Nigeria’s progress, noting that since the national rollout, the number of vaccinated girls across the continent has more than doubled, driven primarily by Nigeria’s leadership.

Mjekula also made an appeal for multi-sectoral collaboration, urging the involvement of private sector giants, from banks to telecoms and philanthropic foundations.

“Health is not just the government’s responsibility. We need to imagine beyond the healthcare we can afford with public funds and work toward the healthcare we want as a society,” she said.

She also called for a business case for investment in HPV prevention and cancer control, saying the task force must work hand-in-hand with all stakeholders.

“Let us go far together. If you want to go quickly, go alone. But if you want to go far, go together,” she said.

The symposium concluded with a call to integrate cancer screening into primary health care services.

It also called for the deployment of cost-effective technologies like self-sampling, addressing myths around vaccine shortages, and ensuring gender-sensitive, data-informed policies.

As Nigeria and the continent advance towards achieving the WHO 90-70-90 cervical cancer elimination targets, the message from experts was clear: “Let us do big and let us do it together”.

The United Nations agencies have reported that in 2024, approximately 89 per cent of infants worldwide, about 115 million children, received at least one dose of the diphtheria, tetanus, and pertussis (DTP) vaccine.This update comes from new national immunisation coverage data released on July 14 by the World Health Organisation (WHO) and the United Nations Children’s Fund (UNICEF).

Nigeria has recorded 145 deaths from Lassa fever as of 2025 Epidemiological Week 25, with a case fatality rate (CFR) of 18.6 percent.

The Nigeria Centre for Disease Control and Prevention (NCDC), disclosed this in its latest report via its official website during the weekend in Abuja.

The NCDC said the week 25 figure marks an increase from 17.

The report, which covered the week of June 16–22, revealed that 781 confirmed cases were reported out of 5,943 suspected cases across 20 states and 101 Local Government Areas (LGAs).

In the current reporting week, 10 new confirmed cases were reported in Ondo and Edo states with a slight increase from the eight cases recorded the previous week.

According to NCDC, 91 per cent of all confirmed cases in 2025 were reported from five states of Ondo (31%), Bauchi (24%), Edo (17%), Taraba (16%) and Ebonyi (3%).

It said that the disease continues to affect young adults predominantly, within the 21 to 30 age group most impacted. Males were slightly more affected, with a male-to-female ratio of 1:0.8.

The Nigerian public health agency, said that despite a decline in the overall number of suspected and confirmed cases compared to 2024, the rise in CFR is raising concerns among health experts.

The agency highlighted late presentation of cases, high treatment costs, and poor health-seeking behaviour as contributing factors to the increased fatality.

It said that no new infections among health workers were recorded in the reporting week, though 23 healthcare workers have been affected cumulatively this year.

The NCDC said it is currently in collaboration with partners, such as the World Health Organisation (WHO), the United States Centers for Disease Control and Prevention (US CDC), ALIMA, the Institute of Human Virology Nigeria (IHVN) and others.

The collaborations, it stated further, have intensified multi-sectoral response efforts to combat the spread of Lassa fever.

It said that, as part of these efforts, Integrate clinical trials are currently ongoing in Ondo State, with After Action Reviews (AARs) conducted in both Ondo and Ebonyi to evaluate the response to the outbreak.

The agency said that clinician sensitisation, community engagement activities and environmental response campaigns have been carried out in identified hotspot areas.

In addition, the NCDC said that it has deployed 10 national rapid response teams to various states, adopting a one health approach to disease control.

To further strengthen infection prevention and control (IPC), the agency launched an IPC e-learning platform and distributed updated Viral Hemorrhagic Fever (VHF) guidelines to health facilities across the country.

The agency said that other efforts also included active contact tracing, surveillance, media engagement and geospatial risk mapping, alongside regular webinars for clinicians and capacity-building sessions nationwide.

The NCDC identified key challenges including poor environmental sanitation and low community awareness, particularly in high-burden LGAs.

It also said that sustained efforts were needed to curb the fatality rate, ensure early detection, and improve public health outcomes.

The NCDC advised Nigerians to maintain proper hygiene, avoid contact with rodents, and seek medical help promptly when experiencing symptoms such as fever, sore throat, vomiting, or unexplained bleeding.

Lassa fever, which was first identified in 1969 in Lassa, Borno, is endemic in Nigeria, with outbreaks occurring annually.

Symptoms range from mild fever and joint pain to severe bleeding from the nose, mouth, and gastrointestinal tract.

The disease is fatal in about 20 percent of cases, particularly when treatment is delayed.

Across West Africa, hundreds of thousands are infected annually, experiencing symptoms such as fever, vomiting and, in severe cases, bleeding.

One of the most troubling complications is hearing loss, which affects about 25 percent of survivors.

The estimated fatality rate is one per cent, but during outbreaks, mortality can rise significantly, particularly among pregnant women and healthcare workers.

In spite of its significant health impact, Lassa fever remains one of the most neglected diseases, with limited resources allocated to its preventions and treatments.

Currently, no licensed vaccines exist, although around 20 candidates are in development, with the most advanced in Phase IIa clinical trials.